Arthur Hung, MD
Radiation Oncology · Portland, ORNPI 1609881119
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 48.0% of the total. Reporting peaked in 2022 at $301 and has fallen 85.6% since, to $43 in 2025.
Across 18 payments — averaging $57.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$495
- Progenics Pharmaceuticals, Inc.$148
- Sumitomo Pharma America, Inc.$126
- Reflexion Medical, Inc.$100
- Boston Scientific$70
- Blue Earth Diagnostics$43
- plus $48 from 3 others
Across 60 payments — averaging $3548.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$213K
What the payments were for
- Food & beverage$1,00798%
- Education$242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 7 | $495 |
| Progenics Pharmaceuticals, Inc. | 1 | $148 |
| Sumitomo Pharma America, Inc. | 1 | $126 |
| Reflexion Medical, Inc. | 4 | $100 |
| Boston Scientific | 1 | $70 |
| Blue Earth Diagnostics | 1 | $43 |
| Myovant Sciences Inc. | 1 | $24 |
| Accuray Incorporated | 1 | $15 |
| Elekta, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PYLARIFY$148
- Varian Ethos Treatment Planning$131
- ORGOVYX$126
- TrueBeam$103
How this compares
$1,031 in reported general payments places this provider in the 75th percentile of 93 radiation oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 157 | $3,252 |
| Oxybutynin Chloride | 31 | $421 |
| Bicalutamide | 12 | $160 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Portland
- Marka CrittendenPortland$20K
- Steven SeungPortland$11K
- Joshua WalkerPortland$9K
- Andrew KeePortland$7K
- Brandon DyerPortland$4K
- Nima NabavizadehPortland$4K
- Amar SrivastavaPortland$4K
- Re-I ChinPortland$3K
- Akanksha RajeursPortland$2K
- Matthew SolhjemPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.